Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2021-04-29 Earnings Release
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
PR_2021-04-29_BOTHE_FY 2020_EN_Final_Long.pdf
Earnings Release Classification · 98% confidence The document explicitly states it announces '2020 full year results' and provides detailed financial highlights for the 'year ending 31 December 2020', including an income statement review for 2020 compared to 2019. This content structure—full-year financial performance, clinical/operational highlights for the year, and outlook—is characteristic of a comprehensive annual financial report. Although it is presented as a press release format, the substance is the full-year financial disclosure. Since the document length is substantial (over 160k characters) and it contains the detailed financial results, it is classified as the Annual Report (10-K) content, rather than just an Earnings Release (ER) or a Report Publication Announcement (RPA). FY 2020
2021-04-29 English
PR_2021-04-29_BOTHE_FY 2020_FR_Final_Long.pdf
Earnings Release Classification · 95% confidence The document is a press release from Bone Therapeutics titled 'Bone Therapeutics publie ses résultats annuels 2020'. It provides a summary of financial highlights (revenue, operating loss, cash position), clinical trial updates, and operational developments for the fiscal year 2020. While it contains substantive financial data and analysis, it is structured as an initial announcement of results (Earnings Release) rather than the full, audited Annual Report (10-K). It follows the standard format for an earnings release, summarizing key performance indicators and management commentary. FY 2020
2021-04-29 French
20210226_BOTHE_Acte-Notaire_S36C-6e21022612020.pdf
AGM Information Classification · 98% confidence The document is a formal legal record, specifically a "procès-verbal" (minutes) drafted by a notary, detailing the proceedings and resolutions of an Extraordinary General Meeting ("assemblée générale extraordinaire") of the company BONE THERAPEUTICS. The key agenda items involve a 'RÉDUCTION DES PRIMES D'ÉMISSION ET DU CAPITAL EN APUREMENT DES PERTES' (Reduction of share premiums and capital to write off losses) and subsequent modification of the articles of association. This type of document, which records shareholder decisions made during a formal meeting, aligns best with the category for AGM Information (AGM-R), as it is the official record of the meeting's outcomes, even though the topic is financial restructuring rather than standard annual business review.
2021-03-01 French
2FR.20210226_BOTHE_Procuration_ AGE.pdf
Proxy Solicitation & Information Statement Classification · 99% confidence The document is titled 'PROCURATION' (Proxy) and explicitly details the process for a shareholder to appoint a representative ('mandataire') to vote at an 'assemblée générale extraordinaire' (Extraordinary General Meeting - EGM) scheduled for February 26, 2021. It includes sections for appointing the proxy, the agenda (which involves capital reduction and statutory changes), voting instructions, and quorum/majority rules. This material is designed to solicit shareholder votes and provide instructions for representation at a general meeting, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). It is not the AGM presentation itself (AGM-R), nor is it the official voting results (DVA).
2021-02-09 French
3EN.Bone Therapeutics_EGM 26 February 2021_Information on shareholders_ rights.pdf
AGM Information Classification · 99% confidence The document explicitly concerns 'INFORMATION CONCERNING THE RIGHTS OF SHAREHOLDERS TO ASK QUESTIONS ON THE OCCASION OF THE EXTRAORDINARY GENERAL MEETING OF THE COMPANY TO BE HELD ON 26 FEBRUARY 2021'. This relates directly to shareholder rights and procedures surrounding a general meeting, specifically the right to ask questions prior to the meeting. This falls under the scope of materials distributed to shareholders in preparation for a meeting, which is best classified as Proxy Solicitation & Information Statement (PSI), as it details procedures shareholders must follow to exercise their rights before a vote/meeting. It is not the AGM presentation itself (AGM-R), nor the voting results (DVA), nor a general management announcement (MANG). Given the focus on shareholder rights and meeting procedures, PSI is the most appropriate fit.
2021-02-09 English
3FR.Bone Therapeutics_AGE 26 février 2021_information_sur_les_droits_des_actionnaires.pdf
AGM Information Classification · 95% confidence The document is titled 'INFORMATIONS SUR LE DROIT DES ACTIONNAIRES DE POSER DES QUESTIONS A L'OCCASION DE L'ASSEMBLEE GENERALE EXTRAORDINAIRE' (Information on the right of shareholders to ask questions at the Extraordinary General Meeting). It details the procedures, deadlines, and conditions for shareholders to submit written questions prior to an upcoming Extraordinary General Meeting (EGM) scheduled for February 26, 2021. This content directly relates to the procedures and rights surrounding a general meeting, which aligns best with the 'AGM Information' category, even though it specifies an EGM rather than an AGM. Since the definition for AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)', and this document concerns shareholder rights related to a general meeting, AGM-R is the most appropriate fit among the specific options, as there is no dedicated EGM code. It is not a proxy statement (PSI) as it focuses on Q&A rights, not solicitation for votes, nor is it a DVA (Voting Results).
2021-02-09 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.